XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment … Read more
XORTX Therapeutics Inc (XRTX) - Net Assets
Latest net assets as of December 2025: $2.85 Million USD
Based on the latest financial reports, XORTX Therapeutics Inc (XRTX) has net assets worth $2.85 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.68 Million) and total liabilities ($820.51K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.85 Million |
| % of Total Assets | 77.68% |
| Annual Growth Rate | 33.4% |
| 5-Year Change | -82.9% |
| 10-Year Change | N/A |
| Growth Volatility | 607.7 |
XORTX Therapeutics Inc - Net Assets Trend (2014–2025)
This chart illustrates how XORTX Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for XORTX Therapeutics Inc (2014–2025)
The table below shows the annual net assets of XORTX Therapeutics Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.85 Million | -14.43% |
| 2024-12-31 | $3.34 Million | -28.12% |
| 2023-12-31 | $4.64 Million | -33.45% |
| 2022-12-31 | $6.97 Million | -58.22% |
| 2021-12-31 | $16.70 Million | +1594.65% |
| 2020-12-31 | $985.17K | +565.31% |
| 2019-12-31 | $-211.72K | -165.85% |
| 2018-12-31 | $321.54K | +149.12% |
| 2017-12-31 | $-654.63K | -106.47% |
| 2016-12-31 | $-317.06K | -364.38% |
| 2014-12-31 | $119.93K | -- |
Equity Component Analysis
This analysis shows how different components contribute to XORTX Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3221721300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $27.64 Million | 968.29% |
| Other Comprehensive Income | $7.84 Million | 274.67% |
| Total Equity | $2.85 Million | 100.00% |
XORTX Therapeutics Inc Competitors by Market Cap
The table below lists competitors of XORTX Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
West Cobar Metals Ltd
AU:WC1
|
$2.46 Million |
|
Lewis Group Limited
JSE:LEW
|
$2.46 Million |
|
Star Gold Corp
OTCQB:SRGZ
|
$2.47 Million |
|
Cibox Inter@ctive S.A.
PA:ALCBX
|
$2.47 Million |
|
NORFOLK SOUTHERN (NFS.SG)
STU:NFS
|
$2.46 Million |
|
Vessel Co. Ltd
KQ:177350
|
$2.46 Million |
|
Origin Global Empire Public Company Limited
BK:EMPIRE
|
$2.46 Million |
|
Silver Range Resources Ltd
PINK:SLRRF
|
$2.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XORTX Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,336,537 to 2,854,942, a change of -481,595 (-14.4%).
- Net loss of 3,708,598 reduced equity.
- New share issuances of 2,255,535 increased equity.
- Other comprehensive income increased equity by 7,894,395.
- Other factors decreased equity by 6,922,927.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.71 Million | -129.9% |
| Share Issuances | $2.26 Million | +79.0% |
| Other Comprehensive Income | $7.89 Million | +276.52% |
| Other Changes | $-6.92 Million | -242.49% |
| Total Change | $- | -14.43% |
Book Value vs Market Value Analysis
This analysis compares XORTX Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.25x to 0.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $1.59 | $0.39 | x |
| 2016-12-31 | $-1.56 | $0.39 | x |
| 2017-12-31 | $-3.10 | $0.39 | x |
| 2018-12-31 | $0.55 | $0.39 | x |
| 2019-12-31 | $-0.36 | $0.39 | x |
| 2020-12-31 | $1.33 | $0.39 | x |
| 2021-12-31 | $15.32 | $0.39 | x |
| 2022-12-31 | $4.71 | $0.39 | x |
| 2023-12-31 | $2.34 | $0.39 | x |
| 2024-12-31 | $1.16 | $0.39 | x |
| 2025-12-31 | $0.60 | $0.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XORTX Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -129.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-129.90%) is above the historical average (-157.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -30.79% | 0.00% | 0.00x | 1.50x | $-48.91K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-383.13K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-408.74K |
| 2018 | -1174.33% | 0.00% | 0.00x | 3.93x | $-3.81 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-464.33K |
| 2020 | -102.35% | 0.00% | 0.00x | 1.82x | $-1.11 Million |
| 2021 | -7.82% | 0.00% | 0.00x | 1.32x | $-2.98 Million |
| 2022 | -100.32% | 0.00% | 0.00x | 1.77x | $-7.69 Million |
| 2023 | -47.34% | 0.00% | 0.00x | 1.18x | $-2.66 Million |
| 2024 | -142.77% | 0.00% | 0.00x | 1.23x | $-5.10 Million |
| 2025 | -129.90% | 0.00% | 0.00x | 1.29x | $-3.99 Million |
Industry Comparison
This section compares XORTX Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XORTX Therapeutics Inc (XRTX) | $2.85 Million | -30.79% | 0.29x | $2.46 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |